Enanta Pharmaceuticals (ENTA) Retained Earnings (2016 - 2025)
Historic Retained Earnings for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to -$404.9 million.
- Enanta Pharmaceuticals' Retained Earnings fell 2534.95% to -$404.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$404.9 million, marking a year-over-year decrease of 2534.95%. This contributed to the annual value of -$404.9 million for FY2025, which is 2534.95% down from last year.
- According to the latest figures from Q3 2025, Enanta Pharmaceuticals' Retained Earnings is -$404.9 million, which was down 2534.95% from -$386.2 million recorded in Q2 2025.
- Enanta Pharmaceuticals' Retained Earnings' 5-year high stood at $97.2 million during Q1 2021, with a 5-year trough of -$404.9 million in Q3 2025.
- For the 5-year period, Enanta Pharmaceuticals' Retained Earnings averaged around -$166.3 million, with its median value being -$178.9 million (2023).
- As far as peak fluctuations go, Enanta Pharmaceuticals' Retained Earnings plummeted by 82408.3% in 2023, and later plummeted by 2534.95% in 2025.
- Enanta Pharmaceuticals' Retained Earnings (Quarter) stood at $18.5 million in 2021, then crashed by 653.41% to -$102.2 million in 2022, then plummeted by 135.31% to -$240.4 million in 2023, then crashed by 43.65% to -$345.3 million in 2024, then decreased by 17.26% to -$404.9 million in 2025.
- Its Retained Earnings stands at -$404.9 million for Q3 2025, versus -$386.2 million for Q2 2025 and -$368.0 million for Q1 2025.